Vitorovic Stefan

SEC source: 0001826967-26-000003 · form4-06102026_040601.xml · derivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,200

Underlying: Common Stock · 10,200 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000950170-25-102491 · ownership.xml · derivative · entry 4

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,155 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

SEC source: 0000950170-25-102491 · ownership.xml · derivative · entry 3

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,928 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

SEC source: 0000950170-25-102491 · ownership.xml · derivative · entry 2

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,068 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

SEC source: 0000950170-25-102491 · ownership.xml · nonDerivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F2 · shares: Represents Restricted Stock Units ("RSUs"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU.

F1 · price: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F2 · price: Represents Restricted Stock Units ("RSUs"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU.

SEC source: 0001415889-25-016675 · form4-06112025_040613.xml · derivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,200

Underlying: Common Stock · 10,200 shares

Expires 2035-06-08

F1 · derivative.exercise_date: The option shall vest in full on the earliest of (i) June 9, 2026, (ii) the date of the Issuer's 2026 Annual Meeting of stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000950170-25-077276 · ownership.xml · nonDerivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 22, 2026 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0001415889-24-017995 · form4-06242024_080632.xml · derivative · entry 3

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,760

Underlying: Common Stock · 11,760 shares

Expires 2034-06-19

F5 · derivative.exercise_date: 1/3rd of the shares subject to the option will vest on June 20, 2025, and the balance will vest in equal monthly installments thereafter over the next 24 months, subject in each case to the continuous service of the Reporting Person to the Issuer through the applicable vesting date.

SEC source: 0001415889-24-017995 · form4-06242024_080632.xml · nonDerivative · entry 2

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By LLC

Disclosed balance after: 27,774

F3 · price: Received in exchange for 51,969 shares of common stock held by Vida Ventures II-A, LLC ("VIDA II-A") of Tectonic pursuant to the same terms and conditions as described in footnote (1) herein.

F4 · ownership.nature: The Reporting Person, through his position as a member of the investment committee of VV Manager, the manager of VIDA II-A, may be deemed to have voting and dispositive power over the shares held by VIDA II-A. The Reporting Person disclaims beneficial ownership of the shares held by VIDA II-A, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-017995 · form4-06242024_080632.xml · nonDerivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By LLC

Disclosed balance after: 1,000,900

F1 · price: Received in exchange for 1,872,873 shares of common stock held by Vida Ventures II, LLC ("VIDA II") of Tectonic Therapeutic, Inc., a Delaware corporation ("Tectonic"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc.

F2 · ownership.nature: The Reporting Person, through his position as a member of the investment committee of VV Manager II, LLC ("VV Manager"), the manager of VIDA II, may be deemed to have voting and dispositive power over the shares held by VIDA II. The Reporting Person disclaims beneficial ownership of the shares held by VIDA II, except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0000950170-24-070843 · ownership.xml · derivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,068

Underlying: Common Stock · 18,068 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option was awarded to the reporting person pursuant to the Issuer's 2021 Stock Option and Incentive Plan. The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 5, 2025 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000950170-24-054700 · ownership.xml · derivative · entry 4

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,928

Underlying: Common Stock · 13,928 shares

Expires 2033-06-07

F3 · derivative.exercise_price: The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability.

F1 · kind: On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000950170-24-054700 · ownership.xml · derivative · entry 3

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,928 shares

Expires 2033-06-07

F1 · kind: On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000950170-24-054700 · ownership.xml · derivative · entry 2

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,155

Underlying: Common Stock · 12,155 shares

Expires 2032-06-09

F3 · derivative.exercise_price: The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability.

F1 · kind: On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2021 Plan and the shares subject to this stock option award are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-054700 · ownership.xml · derivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,155 shares

Expires 2032-06-09

F1 · kind: On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2021 Plan and the shares subject to this stock option award are fully vested and exercisable as of the date hereof.

SEC source: 0000899243-23-015163 · doc4.xml · derivative · entry 3

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,928

Underlying: Common Stock · 13,928 shares

Expires 2033-06-07

F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-22-022159 · doc4.xml · derivative · entry 3

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,155

Underlying: Common Stock · 12,155 shares

Expires 2032-06-09

F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 9, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0001689548-22-000067 · wf-form4_165368680552025.xml · derivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,753

Underlying: Common Stock · 22,753 shares

Expires 2032-05-26

F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on May 26, 2022.

SEC source: 0000899243-22-001650 · doc4.xml · derivative · entry 6

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vida Ventures III-A, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 7,684 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date.

F3 · ownership.nature: The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of of Vida III-A. The Reporting Person is a managing member of Vida III GP and disclaims beneficial ownership of the shares held directly by Vida III-A, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-22-001650 · doc4.xml · derivative · entry 5

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vida Ventures III, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 3,333,245 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date.

F2 · ownership.nature: The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of of Vida III. The Reporting Person is a managing member of Vida III GP and disclaims beneficial ownership of the shares held directly by Vida III, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-22-001650 · doc4.xml · nonDerivative · entry 4

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vida Ventures III-A, L.P.

Disclosed balance after: 11,536

F5 · price: On January 11, 2022, Vida III-A purchased 3,852 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering.

F3 · ownership.nature: The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of of Vida III-A. The Reporting Person is a managing member of Vida III GP and disclaims beneficial ownership of the shares held directly by Vida III-A, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-22-001650 · doc4.xml · nonDerivative · entry 3

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vida Ventures III, L.P.

Disclosed balance after: 5,004,393

F4 · price: On January 11, 2022, Vida III purchased 1,671,148 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering.

F2 · ownership.nature: The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of of Vida III. The Reporting Person is a managing member of Vida III GP and disclaims beneficial ownership of the shares held directly by Vida III, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-22-001650 · doc4.xml · nonDerivative · entry 2

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vida Ventures III-A, L.P.

Disclosed balance after: 7,684

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date.

F3 · ownership.nature: The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of of Vida III-A. The Reporting Person is a managing member of Vida III GP and disclaims beneficial ownership of the shares held directly by Vida III-A, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-22-001650 · doc4.xml · nonDerivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vida Ventures III, L.P.

Disclosed balance after: 3,333,245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date.

F2 · ownership.nature: The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of of Vida III. The Reporting Person is a managing member of Vida III GP and disclaims beneficial ownership of the shares held directly by Vida III, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001689548-21-000061 · wf-form4_162327265301167.xml · derivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,343

Underlying: Common Stock · 22,343 shares

Expires 2031-06-08

F1 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 8, 2021.

SEC source: 0000899243-20-028740 · doc4.xml · derivative · entry 5

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 412,081 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

SEC source: 0000899243-20-028740 · doc4.xml · derivative · entry 4

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 80,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

SEC source: 0000899243-20-028740 · doc4.xml · derivative · entry 3

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 257,853 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

SEC source: 0000899243-20-028740 · doc4.xml · derivative · entry 2

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,939,295 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

SEC source: 0000899243-20-028740 · doc4.xml · nonDerivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,689,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

SEC source: 0001689548-21-000003 · wf-form4a_161350989285647.xml · derivative · entry 6

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 412,081 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

SEC source: 0001689548-21-000003 · wf-form4a_161350989285647.xml · derivative · entry 5

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 80,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

SEC source: 0001689548-21-000003 · wf-form4a_161350989285647.xml · derivative · entry 4

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 257,853 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

SEC source: 0001689548-21-000003 · wf-form4a_161350989285647.xml · derivative · entry 3

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,939,295 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.exercise_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F1 · derivative.expiration_date: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

SEC source: 0001689548-21-000003 · wf-form4a_161350989285647.xml · nonDerivative · entry 2

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,939,329

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

SEC source: 0001689548-21-000003 · wf-form4a_161350989285647.xml · nonDerivative · entry 1

Vitorovic Stefan · CIK 0001826967 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,689,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All series of Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-2.14 basis upon the closing of the Issuer's initial public offering on October 20, 2020 and had no expiration date.

F2 · ownership.nature: These shares are held directly by Vida Ventures, LLC, a United States limited liability company. The Reporting Person is a managing director of Vida Ventures, LLC and is also a member of the board of directors of the Issuer. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.